Biogen (NASDAQ:BIIB) – Equities researchers at Leerink Swann lifted their Q2 2018 earnings estimates for Biogen in a research note issued to investors on Tuesday, April 17th. Leerink Swann analyst G. Porges now anticipates that the biotechnology company will earn $6.43 per share for the quarter, up from their previous forecast of $6.38. Leerink Swann also issued estimates for Biogen’s Q3 2018 earnings at $6.39 EPS and Q4 2018 earnings at $6.48 EPS.
A number of other research firms have also commented on BIIB. Deutsche Bank reaffirmed a “buy” rating and issued a $373.00 price objective on shares of Biogen in a research note on Friday, January 26th. Oppenheimer increased their target price on shares of Biogen from $380.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, January 26th. Jefferies Group reissued a “hold” rating on shares of Biogen in a research note on Friday, January 26th. BMO Capital Markets reissued a “buy” rating on shares of Biogen in a research note on Thursday, January 25th. Finally, Cowen reissued a “buy” rating and set a $408.00 target price on shares of Biogen in a research note on Friday, January 26th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and twenty-one have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $366.49.
NASDAQ:BIIB opened at $263.02 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34. Biogen has a 52 week low of $244.28 and a 52 week high of $370.57. The firm has a market capitalization of $56,705.15, a PE ratio of 12.06, a PEG ratio of 1.48 and a beta of 0.86.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm had revenue of $3.31 billion during the quarter, compared to the consensus estimate of $3.08 billion. During the same period in the prior year, the company posted $5.04 earnings per share. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year.
Hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors purchased a new stake in shares of Biogen in the fourth quarter valued at about $113,000. Prentiss Smith & Co. Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at about $123,000. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Biogen by 77.0% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 174 shares during the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at about $133,000. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at about $149,000. Institutional investors own 88.92% of the company’s stock.
In other Biogen news, EVP Alfred Sandrock sold 743 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $292.00, for a total transaction of $216,956.00. Following the transaction, the executive vice president now owns 6,553 shares in the company, valued at $1,913,476. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 2,296 shares of company stock worth $678,993. Corporate insiders own 0.25% of the company’s stock.
WARNING: “Q2 2018 EPS Estimates for Biogen (BIIB) Raised by Analyst” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/21/q2-2018-eps-estimates-for-biogen-biib-raised-by-analyst.html.
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.